Louisiana House Bill HB907

Louisiana 2026 Regular Session

• Introduced: 2/27/26
• Refer: 2/27/26
• Refer: 3/9/26
• Report Pass: 3/25/26
• Engrossed: 4/1/26
• Refer: 4/7/26
• Report Pass: 4/22/26

Caption

Provides civil and criminal immunity for the distribution or use of Naloxone and other opioid antagonists beyond their shelf-life end date

Impact

The enactment of HB 907 is expected to significantly alter the landscape of opioid overdose response protocols in Louisiana. Specifically, it will protect those who act in good faith to provide Naloxone to individuals believed to be experiencing an overdose, thereby potentially saving lives by eliminating barriers to access and usage. Moreover, healthcare practitioners will not face disciplinary actions from licensing boards for actions made under the provisions of this bill, facilitating a more supportive environment for interventions in overdose cases.

Summary

House Bill 907, introduced by Representative Miller, aims to provide civil and criminal immunity for the distribution and use of Naloxone and other opioid antagonists even if they are past their labeled shelf-life end dates. The bill seeks to promote the wider availability and use of these lifesaving drugs in situations involving opioid overdose. By ensuring immunity from legal liability, it encourages individuals, including healthcare providers, to administer these medications during critical moments without fear of repercussions regarding the expiration dates of the products used.

Sentiment

Discussions surrounding the bill have been largely positive from proponents who view it as a necessary step in combating the opioid crisis. Advocates argue that by reducing fear and legal repercussions associated with administering potentially expired drugs, it fosters a more proactive community response to overdoses. However, some concerns may arise regarding the implications of using medications past their shelf-life, although the bill includes provisions for compliance with federal regulations.

Contention

As HB 907 moves through the legislative process, one potential point of contention might be the balance between ensuring safety in overdose treatment and the implications of extending immunity for expired medications. Critics may argue that promoting the use of expired drugs could lead to health risks, emphasizing the need for oversight and adherence to safety standards. The effectiveness of Naloxone beyond its shelf-life remains a subject for further discussion, ensuring that any adopted measures do not inadvertently compromise patient safety.